Versartis

February 01, 2019

Upcoming events – Ascendis and Lilly hope for growth with pivotal data

Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.

April 10, 2018

Where is the IPO class of 2014-15 now?

A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.

September 22, 2017

Ascendis’s growth spurt comes courtesy of Versartis

August 04, 2017

Upcoming events – FDA decision for Adamas in Parkinson’s dyskinesia and growth data for Versartis

September 21, 2015

Versartis grows taller, but still a way to go

June 26, 2015

Alexion’s twin approval highlights industry’s love of orphans

June 12, 2015

Upcoming events: Data from Redhill in ulcers and Ascendis in growth deficiencies

January 21, 2015

JP Morgan and the gift that keeps on giving

December 15, 2014

Growth hormone pact a perplexing deal for post-Astra Pfizer